BBV Review

Advertisement

Hepatitis C

People with chronic Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) are at risk of serious liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, supplementary information such as prevalence data are needed. People with chronic Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) are at risk of serious liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, supplementary information such as prevalence data are needed.   Author: Dr Siamak Tonekaboni
Summary: The pediatric and adolescent population is often overlooked in surveys and the burden of disease is essentially unknown particularly in countries with high prevalence rates. It is imperative to determine the brunt of the disease in the pediatric population to fulfill the WHO’s global HCV elimination goals, also diagnose and cure children at an early age before adolescence and behaviors associated with high risk of transmission.
Summary: Most recent and up to date review on HCV diagnosis by Professor Francesco Negro from University Hospital of Geneva, Switzerland. An extensive review on clinical aspects of HCV diagnosis as well as review of most recent technologies and tools available.
Summary: The World Hepatitis Summit is a public policy three day event bringing together a global audience of civil society groups, WHO and its Member States, patient organisations from the World Hepatitis Alliance’s 249 organisational members, policy-makers, public health scientists and funders.
A personal perspective on how Treatment Action Groups (TAG) help improve access to life saving drugs for Hepatitis C positive patients, but still more needs to be done.  
Response-guided therapy leads to complete cure after three weeks of all-oral triple-direct acting antiviral regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI study)  
Riksföreningen Hepatit C (RHC) is a small organization with fewer than 600 members in the whole country. There are two local organizations, in Stockholm (LHC Stockholm) and in Gothenburg (LHC Västra Götaland). There are seven members on the board of the national organization, of which three are active on a national level and one each at a local level in Stockholm and in Gothenburg. Our chairwoman, Suzanne Borén Andersson, works mostly with domestic affairs and concerns, whilst myself, Tove Frisch, works mostly on establishing international contacts and networks. In addition the organization has a very reliable accountant, Michael Mogensen.
The diagnostic strategy of HCV infections is usually based on three essential principles: cost, convenience and the ability to link it to HCV treatment.
Where does the new AbbVie Viekira Pak regimen fit and what challenges remain?
Today, in contrast to Interferon therapy the new direct acting antivirals (DAAs)  for HCV can cure patients much faster, with fewer adverse effects, but their cost presents a big challenge to global health systems so what is best solution for this problem?
Page 1 of 2

Twitter Updates

BBV Review RT @HenryEChang: Sustainable Development Goals for HBV elimination in South Africa: challenges, progress & the road ahead→https://t.co/TCu…
Wednesday, 22 May 2019 09:04
BBV Review RT @grahamscooke: Two helpful pieces on HCV reinfection from @GregDore2 @ProfJohnDillon at a time when we're trying to get access to retrea…
Sunday, 05 May 2019 13:34
BBV Review RT @HenryEChang: Biological basis for functional cure of chronic hepatitis B→https://t.co/vGzHbrJkbs via Drs. MG Martinez, Barbara Testoni…
Sunday, 05 May 2019 13:33
BBV Review RT @HenryEChang: Prevalence, incidence, & outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review & meta-anal…
Sunday, 05 May 2019 13:31

Events & Conferences

For accurate and independent information on blood borne viruses, subscribe to our free newsletter.